Background/Aims: Anti-tumor necrosis factor (TNF) antibodies have clinical efficiency only in a subgroup of patients with inflammatory bowel diseases (IBD). Prediction of clinical response is a critical clinical problem. Physiological intermolecular modification spectroscopy (PIMS) is a label-free technology performed in physiological conditions. PIMS enables real-time monitoring of dynamic molecular resonance of entire proteins and macromolecules of an individual. The aim of this study was to explore the capacity of PIMS to discriminate IBD patients regarding response to anti-TNF treatment. Methods: Protein extracts of peripheral blood mononuclear cells (PBMC) from 30 outpatients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) and treated with infliximab were subjected to PIMS analysis in a blinded transversal study. Total protein from each patient's PBMCs was challenged with infliximab. Dynamic changes in macromolecular interaction were registered while the temperature rose from -37 to 37°C. Individual macromolecular volume and molecular elasticity were determined for each patient. Results: Clinical data revealed that 67% of UC and 79% of CD patients responded to infliximab therapy during the 3-month study period based on their respective clinical activity score. These results confirm that PIMS data predicted response to anti-TNF therapy with an accuracy of 96%. Conclusion: PIMS stratified IBD patients into two groups, responders and nonresponders, which correlated with the clinical efficacy of anti-TNF therapy. PIMS seems to be a powerful technology to adapt IBD treatment to the individual patient. Further studies with PIMS might enable to predict clinical response to biological treatment in IBD patients before the therapy is initiated.

Keywords:
Anti-tumor necrosis factor therapy, Crohn’s disease, Inflammatory bowel disease, Physiological intermolecular modification spectroscopy, Ulcerative colitis
1.
Reenaers C, Louis E, Belaiche J: Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol 2010;3:99-106.
2.
Ghosh S, Panaccione R: Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010;3:239-258.
3.
Rutgeers P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
4.
Hanauer SB, Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333.
5.
D'Haens G: Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007;56:725-732.
6.
Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J: Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012;6:143-153.
7.
Moore RA, Derry S: Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182.
8.
Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Hugot JP, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, Mowat C, Newman W, Panés J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, Stokkers PC, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, Hakonarson H, Daly MJ, Parkes M: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
9.
Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, Essers J, Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Büning C, Cohain A, Cichon S, D'Amato M, De Jong D, Devaney KL, Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H; International IBD Genetics Consortium (IIBDGC), Silverberg MS, Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, Barrett JC, Cho JH: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-124.
10.
Stockmayer WH, Stanley HE: Light-scattering measurement of interactions between unlike polymers. J Chem Phys 1950;18:153-154.
11.
Timasheff SN, Robinson RA: The location of electrostatic charges in Kirkwood's model of organic ions. J Am Chem Soc 1957;79:782.
12.
Abbott NL, Blankschtien D, Hatton TA: Protein partitioning in two-phase aqueous polymer systems. 1. Novel physical pictures and a scaling-thermodynamic formulation. Macromolecules 1992;25:3917.
13.
Moon YU, Curtis RA, Anderson CO, Blanch HW, Prausnitz JM: Protein-protein interactions in aqueous ammonium sulfate solutions. Lysozyme and bovine serum albumin (BSA). J Solution Chem 2000;29:699.
14.
Skouri M, Lorber B, Giege R, Munch JP, Candau JS: Effect of macromolecular impurities on lysozyme solubility and crystallizability: dynamic light scattering, phase diagram, and crystal growth studies. J Cryst Growth 1995;152:209-220.
15.
Narayanan J, Liu XY: Protein interactions in undersaturated and supersaturated solutions: a study using light and x-ray scattering. Biophys J 2003;84:523-532.
16.
Liu W, Bratko D, Prausnitz JM, Blanch HW: Effect of alcohols on aqueous lysozyme-lysozyme interactions from static light-scattering measurements. Biophys Chem 2004;107:289-298.
17.
van den Berg B, Chung EW, Robinson CV, Mateo PL, Dobson CM: The oxidative refolding of hen lysozyme and its catalysis by protein disulfide isomerase. EMBO J 1999;18:4794-4803.
18.
Cheung MS, Klimov D, Thirumalai D: Molecular crowding enhances native state stability and refolding rates of globular proteins. Proc Natl Acad Sci USA 2005;102:4753-4758.
19.
Ellis RJ, Minton AP: Protein aggregation in crowded environments. Biol Chem 2006;387:485-497.
20.
Richter K, Nessling M, Lichter P: Macromolecular crowding and its potential impact on nuclear function. Biochem Biophys Acta 2008;1783:2100-2107.
21.
Fullerton GD, Cameron IL: Water compartments in cells. Methods Enzymol 2007;428:1-28.
22.
Graziano G: Hydration entropy of polar, nonpolar charged species. Chem Phys Lett DOI: 10.1016/J.cplett.2009.07.01.
23.
Arrondo JL, Muga A, Castresana J, Goñi FM: Quantitative studies of the structure of proteins in solution by Fourier-transform infrared spectroscopy. Prog Biophys Mol Biol 1993;59:23-56.
24.
Siebert F: Infrared spectroscopy applied to biochemical and biological problems. Methods Enzymol 1995;246:501-526.
25.
Jackson M, Mantsch HH: The use and misuse of FTIR spectroscopy in the determination of protein structure. Crit Rev Biochem Mol Biol 1995;30:95-120.
26.
Goormaghtigh E, Cabiaux V, Ruysschaert JM: Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. III. Secondary structures. Subcell Biochem 1994;23:405-450.
27.
Arrondo JL, Goñi FM: Structure and dynamics of membrane proteins as studied by infrared spectroscopy. Prog Biophys Mol Biol 1999;72:367-405.
28.
Haris PI, Chapman D: Does Fourier-transform infrared spectroscopy provide useful information on protein structures? Trends Biochem Sci 1992;17:328-333.
29.
Dioumaev AK: Infrared methods for monitoring the protonation state of carboxylic amino acids in the photocycle of bacteriorhodopsin. Biochemistry (Mosc) 2001;66:1269-1276.
30.
Kauffmann E, Darnton NC, Austin RH, Batt C, Gerwert K: Lifetimes of intermediates in the beta-sheet to alpha-helix transition of beta-lactoglobulin by using a diffusional IR mixer. Proc Natl Acad Sci USA 2001;5:98:6646-6649.
31.
Pozo Ramajo A, Petty SA, Starzyk A, Decatur SM, Volk M: The alpha-helix folds more rapidly at the C-terminus than at the N-terminus. J Am Chem Soc 2005;127:13784-13785.
32.
Lin S-Y, Li MJ, Cheng WT: FT-IR and Raman vibrational microspectroscopies used for spectral biodiagnosis of human tissues. Spectroscopy 2007;21:1-30.
33.
Yang C, Brown JN, Kopple KD: Peptide water association in peptide crystals. Int J Peptide Res 1979;14:12-20.
34.
Klotz IM: Protein hydration and behaviour: many aspects of protein behavior can be interpreted in terms of frozen water of hydration. Science 1958;128:815-822.
35.
Frank HS, Evans MW: Free volume and entropy in condensed systems. J Chem Phys 1945;13:507-532.
36.
Paker KJ: Nuclear spin relaxation studies of molecules absorbed on surfaces; in Einsley JW, Feeney J, Suteliffe LH (eds): Progress in Nuclear Magnetic Resonance Spectroscopy. New York, Pergamon Press, 1971.
37.
Nichita C, Stelle M, Vavricka S, El-Wafa Ali A, Ballabeni P, de Saussure P, Straumann A, Rogler G, Michetti P: Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion 2010;81:78-85.
38.
Rutgeers P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-2476.
39.
Vermeire S, Van Assche G, Rutgeerts P: C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004;10:661-665.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.